Actinium Pharmaceuticals
ATNM
69 hedge funds and large institutions have $10.2M invested in Actinium Pharmaceuticals in 2024 Q4 according to their latest regulatory filings, with 14 funds opening new positions, 27 increasing their positions, 14 reducing their positions, and 17 closing their positions.
1,417% more call options, than puts
Call options by funds: $91K | Put options by funds: $6K
93% more repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 14
1.09% less ownership
Funds ownership: 27.16% → 26.07% (-1.1%)
4% less funds holding
Funds holding: 72 → 69 (-3)
18% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 17
36% less capital invested
Capital invested by funds: $15.9M → $10.2M (-$5.65M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
+$171K |
| 2 |
Morgan Stanley
New York
|
+$159K |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$154K |
| 4 |
Renaissance Technologies
New York
|
+$98.4K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$80.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AQR Capital Management
Greenwich,
Connecticut
|
-$532K |
| 2 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$405K |
| 3 |
Verition Fund Management
Greenwich,
Connecticut
|
-$314K |
| 4 |
XT
XTX Topco
George Town,
Cayman Islands
|
-$181K |
| 5 |
BGIM
Brandywine Global Investment Management
Philadelphia,
Pennsylvania
|
-$169K |
ATNM Hedge Fund Activity: Q4 2024 in Review
69 of the 7,607 institutional investors tracked by Wall St. Rank reported a position in Actinium Pharmaceuticals (ATNM) for Q4 2024, worth a combined $10.2M — down 36% from $15.9M a quarter earlier.
Sellers outnumbered buyers: 17 funds closed out of ATNM and 14 opened new positions — a net loss of 3 holders — while 14 trimmed existing stakes and 27 added.
The largest buyer was JP Morgan Chase, adding an estimated $171K. The largest seller was AQR Capital Management, cutting an estimated $532K.
- 69 institutional investors held Actinium Pharmaceuticals (ATNM) as of Q4 2024, down from 72 in Q3 2024.
- Funds reported $10.2M of Actinium Pharmaceuticals stock for Q4 2024, down 36% quarter-over-quarter.
- 14 funds opened new Actinium Pharmaceuticals positions in Q4 2024 and 17 closed out, a net change of -3 holders.
- The largest Actinium Pharmaceuticals buyer in Q4 2024 was JP Morgan Chase, an estimated $171K added.
- The largest Actinium Pharmaceuticals seller in Q4 2024 was AQR Capital Management, an estimated $532K sold.
Based on aggregated 13F filings for Q4 2024.